Immunogenic Cell Death in Hematological Malignancy Therapy.

Area of Science:

• Immunology
• Oncology
• Cell Death Research

Background:

• Hematological malignancies often relapse or develop drug resistance despite treatment advancements.
• Disruptions in the tumor microenvironment play a significant role in the development of these cancers.
• Regulated cell death (RCD) mechanisms, particularly immunogenic cell death (ICD), are emerging as critical factors in cancer therapy.

Purpose of the Study:

• To review the current understanding of inducing immunogenic cell death (ICD) in hematological malignancies.
• To explore the potential of combining ICD inducers with existing treatment strategies for these cancers.

Main Methods:

• Literature review of studies on ICD induction in hematological malignancies.
• Analysis of research on combination therapies involving ICD inducers.

Main Results:

• Immunogenic cell death (ICD) triggers adaptive immune responses through damage-associated molecular patterns (DAMPs).
• ICD presents a novel immunotherapeutic strategy for treating hematological malignancies.
• Combining ICD inducers with other treatments shows potential for overcoming relapse and drug resistance.

Conclusions:

• Immunogenic cell death (ICD) is a viable therapeutic strategy for hematological malignancies.
• Combination approaches involving ICD inducers warrant further investigation for enhanced treatment efficacy.
• Targeting ICD may offer new avenues to address treatment resistance in blood cancers.